- Clinical-stage biopharmaceutical company focused on rare respiratory diseases – Savara (SVRA) proposed an underwritten public offering of approximately 23.81 million shares at a price of $4.20 per share.
- Total gross proceeds of $130 million expected
- Subscribers have a 30-day option to redeem
